R-Tech Ueno Report issue

For profit Phase 2 Phase 3
Founded: Osaka Japan (1989)
Status: Acquired by Sucampo (2015) → now Mallinckrodt (2013) (2017)

Organization Overview

First Clinical Trial
2013
NCT01786395
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

unoprostone isopropyl (rescula) (1 trial)

Drugs in Phase 2 Trials (1)

ru-101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Retinitis (Phase 3)

Retinitis Pigmentosa (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2